STI-Stiftung

GenXBioscience AG is a Swiss company operating at the intersection of biotechnology and medtech, uniquely combining innovations from both sectors to develop cutting-edge medical technologies. Positioned at this dynamic convergence, the company utilizes advanced biotechnological techniques to engineer state-of-the-art medtech solutions. By bringing together biotechnology and medtech, the company is striving to provide innovative solutions that address critical unmet medical needs. The primary mission is to harness the power of next-generation sequencing to decode and analyze complex genetic information at an unprecedented scale and speed. Through this technology, the company identified novel biomarkers for celiac disease and non-celiac gluten/wheat sensitivity diagnosis.

The STI`s loan (approved 2024) will be used to finance in-part the development of in vitro diagnostics prototypes for the diagnosis of celiac disease and non-celiac gluten/wheat sensitivity.